Cianna's nonradioactive, long-term breast tumor localization implant gets FDA OK

The Savi Scout tumor localization implant remains inactive until a surgeon activates the device during a surgical biopsy or lumpectomy. (Cianna Medical)

The FDA cleared Cianna Medical’s breast tumor localization system, the first device of its kind to be FDA-cleared for long-term use.

Cianna’s Savi Scout reflector is a nonradioactive implant for the wire-free localization of breast tumors. While imaging can turn up cancerous tissue, not all breast tumors can be felt through the skin. In these cases, a wire is inserted or a radioactive “seed” is implanted into the cancerous tissue to help doctors locate the tumor during surgery later.

There are no restrictions on how long the Scout device may remain in the body, giving physicians more flexibility in treatment plans. Patients with a radioactive implant must take precautions until their implant is removed, but patients implanted with the Scout may continue with their usual activities, the company said in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: Dune Medical scores $12M to take MarginProbe beyond breast cancer

The 4-millimeter Scout implant doesn’t affect a patient’s ability to undergo an MRI scan and is inactive until it is activated during a lumpectomy or surgical biopsy, the company said.

The system uses radar technology to spot tumors with an accuracy of ±1 millimeter.

“Achieving this milestone significantly advances Cianna Medical’s mission to reduce the burden breast cancer treatment places on women and their families,” said CEO Jill Anderson in the statement. “I applaud the vision of all our physicians and health systems who are leading the way in offering a new standard of care in breast tumor localization.”

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.